FY2020 Earnings Forecast for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Issued By Wedbush

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Wedbush increased their FY2020 earnings estimates for shares of Intercept Pharmaceuticals in a report released on Monday. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will post earnings of $9.57 per share for the year, up from their previous estimate of $9.28. Wedbush currently has a “Buy” rating on the stock.

Several other analysts also recently commented on ICPT. Oppenheimer Holdings, Inc. reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, April 12th. Cowen and Company reiterated a “buy” rating and issued a $225.00 target price on shares of Intercept Pharmaceuticals in a report on Monday, April 24th. Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 1st. Cantor Fitzgerald set a $60.00 target price on shares of Intercept Pharmaceuticals and gave the company a “sell” rating in a report on Thursday, May 4th. Finally, Laidlaw upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 target price for the company in a report on Friday, May 5th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $196.39.

ILLEGAL ACTIVITY WARNING: “FY2020 Earnings Forecast for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Issued By Wedbush” was reported by BNB Daily and is the property of of BNB Daily. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/13/fy2020-earnings-forecast-for-intercept-pharmaceuticals-inc-nasdaqicpt-issued-by-wedbush-updated.html.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded down 5.20% on Wednesday, hitting $105.00. 1,048,789 shares of the stock were exchanged. Intercept Pharmaceuticals has a 1-year low of $96.63 and a 1-year high of $177.93. The stock’s 50-day moving average is $124.94 and its 200-day moving average is $118.29. The stock’s market cap is $2.63 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating analysts’ consensus estimates of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 119.17%. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter last year, the firm posted ($3.14) EPS. The company’s quarterly revenue was up 459.6% on a year-over-year basis.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 698 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $110.73, for a total transaction of $77,289.54. Following the completion of the transaction, the insider now owns 24,711 shares in the company, valued at $2,736,249.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel G. Welch sold 217 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the transaction, the director now owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The disclosure for this sale can be found here. Insiders have sold 45,583 shares of company stock valued at $5,905,154 in the last quarter. Company insiders own 4.50% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares in the last quarter. US Bancorp DE acquired a new position in shares of Intercept Pharmaceuticals during the first quarter worth $130,000. IFP Advisors Inc raised its position in shares of Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 730 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Intercept Pharmaceuticals during the first quarter worth $170,000. Finally, Pacer Advisors Inc. raised its position in shares of Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares in the last quarter. Hedge funds and other institutional investors own 84.27% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply